Cellectis (Cellectis) EPS (Basic) : $-1.78 (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Cellectis EPS (Basic)?

Cellectis's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.70. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.78.

Cellectis's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.70. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.78.

Cellectis's EPS without NRI for the three months ended in Dec. 2023 was $-0.90. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -1.93.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Cellectis EPS (Basic) Historical Data

The historical data trend for Cellectis's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis EPS (Basic) Chart

Cellectis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-2.41

-1.91

-2.55

-2.33

-1.77

Cellectis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-0.59	-0.58	-0.19	-0.31	-0.70

Cellectis EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cellectis's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-101.059	-	0)	/	57.013
	=	-1.77

Cellectis's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-42.862	-	0)	/	65.355
	=	-0.66

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.78

Cellectis (NAS:CLLS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Cellectis EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Cellectis's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis (Cellectis) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVAA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.